Overview

* Health Catalyst Q3 2025 revenue remains flat year-over-year at $76.3 mln

* Adjusted EBITDA for Q3 2025 beats analyst expectations

* Net loss for Q3 2025 widens to $22.2 mln from $14.7 mln last year

Outlook

* Health Catalyst expects Q4 2025 revenue of $73.5 mln

* Company anticipates Q4 2025 adjusted EBITDA of $13.4 mln

* Health Catalyst ( HCAT ) reaffirms full-year 2025 revenue guidance at $310 mln

Result Drivers

* STRATEGIC FOCUS - Co attributes results to focus on high-impact solutions with proven ROI

* COST MANAGEMENT - Improved gross margin attributed to cost management efforts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $76.32

Revenue mln

Q3 Net -$22.23

Income mln

Q3 Beat $12 mln $10.70

Adjusted mln (12

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy."

* Wall Street's median 12-month price target for Health Catalyst Inc ( HCAT ) is $4.00, about 29.3% above its November 7 closing price of $2.83

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)